Image For Activity Cover
Advanced Heart Failure Therapies for Hypertrophic Cardiomyopathy: State-of-the-Art Review and an Updated Analysis From UNOS (JACC Heart Failure November 2023)

Hypertrophic cardiomyopathy (HCM) is most commonly associated with obstructive symptoms and sudden cardiac death; however, predominantly nonobstructive advanced heart failure in HCM, marked by medically refractory disease with severe functional impairment, occurs in 5% to 7% of patients with HCM.


JACC Heart Failure Editor-in-Chief
Biykem Bozkurt, MD, PhD, FACC 

Deputy Editor
Akshay S. Desai, MD, MPH 

JACC Heart Failure CME/MOC Editor
Kenneth A. Ellenbogen, MD

Yevgeniy Khariton, MD 

Important Dates

Date of Release: November 6, 2023
Term of Approval/Date of CME/MOC Expiration: November 5, 2024

Availability: On-Demand
Expires on Oct 31, 2024
Cost: FREE
Credit Offered:
1 CME Credit
1 ABIM-MOC Point
Android App Download IOS App Download Powered By